- Home
- CDNA vs RCUS Comparison
CDNA vs RCUS Comparison
Compare CDNA & RCUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CDNA
- RCUS
- Stock Information
- Founded
- CDNA 1998
- RCUS 2015
- Country
- CDNA United States
- RCUS United States
- Employees
- CDNA N/A
- RCUS N/A
- Industry
- CDNA Medical Specialities
- RCUS Biotechnology: Pharmaceutical Preparations
- Sector
- CDNA Health Care
- RCUS Health Care
- Exchange
- CDNA Nasdaq
- RCUS Nasdaq
- Market Cap
- CDNA 1.1B
- RCUS 1.2B
- IPO Year
- CDNA 2014
- RCUS 2018
- Fundamental
- Price
- CDNA $22.94
- RCUS $13.42
- Analyst Decision
- CDNA Buy
- RCUS Buy
- Analyst Count
- CDNA 8
- RCUS 12
- Target Price
- CDNA $26.43
- RCUS $34.50
- AVG Volume (30 Days)
- CDNA 823.5K
- RCUS 632.2K
- Earning Date
- CDNA 02-26-2025
- RCUS 02-19-2025
- Dividend Yield
- CDNA N/A
- RCUS N/A
- EPS Growth
- CDNA N/A
- RCUS N/A
- EPS
- CDNA N/A
- RCUS N/A
- Revenue
- CDNA $312,775,000.00
- RCUS $263,000,000.00
- Revenue This Year
- CDNA $20.27
- RCUS $127.65
- Revenue Next Year
- CDNA $11.76
- RCUS N/A
- P/E Ratio
- CDNA N/A
- RCUS N/A
- Revenue Growth
- CDNA 5.26
- RCUS 119.17
- 52 Week Low
- CDNA $7.42
- RCUS $12.53
- 52 Week High
- CDNA $34.84
- RCUS $20.31
- Technical
- Relative Strength Index (RSI)
- CDNA 53.43
- RCUS 39.20
- Support Level
- CDNA $21.96
- RCUS $12.83
- Resistance Level
- CDNA $23.80
- RCUS $13.56
- Average True Range (ATR)
- CDNA 1.53
- RCUS 0.58
- MACD
- CDNA 0.09
- RCUS -0.01
- Stochastic Oscillator
- CDNA 45.88
- RCUS 35.86
About CDNA CareDx Inc.
CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre-and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically the company generates the majority of its revenue from the United States. The company generates major revenue from the Testing services.
About RCUS Arcus Biosciences Inc.
Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB598, Casdatifan among others. Arcus conducts clinical trials for different types of cancers such as Lung, Colorectal, Pancreatic, and others. The company operates through a single segment which is the business of developing and commercializing immunotherapies.